FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
复制标题
DOI：
10.1038/bjc.2011.43
复制
发表时间：
2011-03-29
影响因子：
8.8
通讯作者：
Conte, P. F.
中科院分区：
文献类型：
--
作者：
Bertolini, F.;Malavasi, N.;Scarabelli, L.;Fiocchi, F.;Bagni, B.;Del Giovane, C.;Colucci, G.;Gerunda, G. E.;Depenni, R.;Zironi, S.;Fontana, A.;Pettorelli, E.;Luppi, G.;Conte, P. F.
在结直肠癌肝转移(CLM)患者中，R0切除显着提高了总存活率(OS)。在这篇报道中，我们介绍了FOLFOX6+贝伐单抗在非最佳可切除CLM患者中的II期试验结果。患者接受了6个周期的FOLFOX6+5个贝伐单抗。没有达到可切除性的患者接受了每个额外的六个周期。在基线和开始治疗后1个月内再次进行PET-CT检查。从2005年9月至2009年7月，纳入21例患者(男性/女性：15/6；中位年龄：65岁)。客观缓解(OR)12例(完全缓解(CRS)57.1%，部分缓解(PR)9例)，1例术前死于毒性反应。根治性手术13例(61.9%)。3例(23%)有病理性CR(PCR)。6例(46.1%)术后出现轻微并发症。经过中位38.8个月的随访，中位OS为22.5个月。PET-CT标准摄取值最大值下降至少1个单位的患者有更长的无进展生存期(中位无进展生存期：22个月比14个月，P=0.001)。FOLFOX6+贝伐单抗不增加术后并发症，可切除率和PCR率高。PET-CT的早期改变似乎预示着较长的PFS。
In patients with colorectal liver metastases (CLM) R0 resection significantly improves overall survival (OS). In this report, we present the results of a phase II trial of FOLFOX6+bevacizumab in patients with non-optimally resectable CLM. Patients received six cycles of FOLFOX6+ five of bevacizumab. Patients not achieving resectability received six additional cycles of each. A PET-CT was performed at baseline and again within 1 month after initiating treatment. From September 2005 to July 2009, 21 patients were enrolled (Male/Female: 15/6; median age: 65 years). An objective response (OR) was documented in 12 cases (57.1% complete responses (CRs): 3, partial response (PR): 9); one patient died from toxicity before surgery. Thirteen patients underwent radical surgery (61.9%). Three (23%) had a pathological CR (pCR). Six patients (46.1%) experienced minor postsurgical complications. After a median 38.8-month follow-up, the median OS was 22.5 months. Patients achieving at least 1 unit reduction in Standard uptake value (SUV)max on PET-CT had longer progression-free survival (PFS) (median PFS: 22 vs 14 months, P=0.001). FOLFOX6+bevacizumab does not increase postsurgical complications, yields high rates of resectability and pCR. Early changes in PET-CT seem to be predictive of longer PFS.
登录
查看更多内容
影响因子：
120.7
作者：
Chun, Yun Shin;Vauthey, Jean-Nicolas;Boonsirikamchai, Piyaporn;Maru, Dipen M.;Kopetz, Scott;Palavecino, Martin;Curley, Steven A.;Abdalla, Eddie K.;Kaur, Harmeet;Charnsangavej, Chusilp;Loyer, Evelyne M.
通讯作者：
Loyer, Evelyne M.
影响因子：
45.3
作者：
Kesmodel, Susan B.;Ellis, Lee M.;Feig, Barry W.
通讯作者：
Feig, Barry W.
影响因子：
45.3
作者：
Benoist, Stephane;Brouquet, Antoine;Nordlinger, Bernard
通讯作者：
Nordlinger, Bernard
影响因子：
45.3
作者：
Blazer, Dan G., III;Kishi, Yoji;Vauthey, Jean-Nicolas
通讯作者：
Vauthey, Jean-Nicolas
对结直肠癌的可切除肝转移的FOLFOX4和手术的围手术性化疗（EORTC组间试验40983）：一项随机对照试验。
影响因子：
168.9
作者：
Nordlinger, Bernard;Sorbye, Halfdan;Glimelius, Bengt;Poston, Graeme J.;Schlag, Peter M.;Rougier, Philippe;Bechstein, Wolf O.;Primrose, John N.;Euan, T. Walpole;Finch-Jones, Meg;Jaeck, Daniel;Mirza, Darius;Parks, Rowan W.;Collette, Laurence;Praet, Michel;Bethe, Ullrich;Van Cutsem, Eric;Scheithauer, Werner;Gruenberger, Thomas
通讯作者：
Gruenberger, Thomas